Southeast Renal Research Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.serri.net
Clinical Trials
7
Active:0
Completed:1
Trial Phases
2 Phases
Phase 2:3
Phase 4:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (50.0%)Phase 4
3 (50.0%)Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis
Phase 2
- Conditions
- Arteriovenous Fistula Occlusion
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Southeast Renal Research Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03106948
- Locations
- 🇺🇸
Southeast Renal Research Institute, Chattanooga, Tennessee, United States
Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Southeast Renal Research Institute
- Registration Number
- NCT03042637
- Locations
- 🇺🇸
Nephronet, Chattanooga, Tennessee, United States
Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders
Phase 2
- Conditions
- Chronic Kidney DiseaseSleep DisorderEnd Stage Renal Disease
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Southeast Renal Research Institute
- Target Recruit Count
- 53
- Registration Number
- NCT01922999
- Locations
- 🇺🇸
Southeast Renal Research Institute, Chattanooga, Tennessee, United States
Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury
Phase 4
Withdrawn
- Conditions
- Kidney Failures, Acute
- Interventions
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Southeast Renal Research Institute
- Registration Number
- NCT01073189
- Locations
- 🇺🇸
Erlanger Medical Center, Chattanooga, Tennessee, United States
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Southeast Renal Research Institute
- Target Recruit Count
- 15
- Registration Number
- NCT01028287
- Locations
- 🇺🇸
Southeast Renal Research Institute, Chattanooga, Tennessee, United States
- Prev
- 1
- 2
- Next
News
No news found